Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Vigna, Ernesto  [Clear All Filters]
2024
Martino EAntonia, Vigna E, Bruzzese A, Labanca C, Mendicino F, Lucia E, Olivito V, Zimbo A, Torricelli F, Neri A, et al. Selinexor in multiple myeloma. Expert Opin Pharmacother. 2024.
2021
Morabito F, Zamagni E, Conticello C, Pavone V, Palmieri S, Bringhen S, Galli M, Mangiacavalli S, Derudas D, Rossi E, et al. Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients. Eur J Haematol. 2021.
Morabito F, Tripepi G, Del Poeta G, Mauro FRomana, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Varettoni M, et al. Assessment of the 4-factor score: retrospective analysis of 586 cll patients receiving ibrutinib. A campus cll study. Am J Hematol. 2021.
Morabito F, Tripepi G, Del Poeta G, Mauro FRomana, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Bossio S, et al. Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine. Results of study on 486 cases outside clinical trials. Am J Hematol. 2021.
Morabito F, Del Poeta G, Mauro FRomana, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Bossio S, Varettoni M, et al. TP53 disruption as a risk factor in the era of targeted therapies: a multicenter retrospective study of 525 chronic lymphocytic leukemia cases. Am J Hematol. 2021.
2019
Morabito F, Recchia AGrazia, Vigna E, Botta C, Skafi M, Abu-Rayyan M, Atrash M, Galimberti S, Morabito L, Al-Janazreh H, et al. An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma. Expert Opin Pharmacother. 2019:1-10.